About BioGene
BioGene is a Healthcare company based in Peterborough (United Kingdom) founded in 1993. Manufacturer of specialist molecular biology analytical instruments and reagents. BioGene offers products and services including CENOS and SoftGenetics Solutions. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Genomics. Its legal entity is BIOGENE LIMITED.
Company details
BioGene is a molecular biology company based in Cambridge UK that manufactures reagents and instruments for assay design and development, DNARNA purification, amplification and analysis. As of September 2016, the company is also in the process of developing specialized instruments for direct PCR amplification from crude samples, and for POC detection of sepsis called QuRapID and QuType, respectively. Both the instruments are based on the companys proprietary UltraRapid PCR system that consists of a single tube DNA extraction and PCR process and associated reagents and instrumentation. QuRapID is designed for rapid identification of bacteria directly from primary samples using a multiplexed RT-PCR approach. QuType is in development as a POC device for simple and rapid diagnosis of sepsis in patients using the UltraRapid PCR platform.
- Latest Funding Round$700K (USD), Post-IPO
Dec 2009
- Investors
Products & Services of BioGene
BioGene offers a comprehensive portfolio of products and services, including CENOS and SoftGenetics Solutions.
Portable system for rapid RT-qPCR testing from crude samples worldwide.
Tools for genetic analysis in diagnostic applications.
Apps and channels of BioGene
its YouTube channel BioGene has 3 subscribers.
Funding Insights of BioGene
- Total Rounds 2
- Last Round Post-IPO — $700,000
- First Round $307,000
(Feb 2007)
- Investors Count 1
All 2 funding rounds of BioGene with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2009 | $700,000 | Post-IPO | – | – | – |
| Feb 2007 | $307,000 | Grant | – | – |
1 investors in total: 1 institutional.
Investors in BioGene
BioGene has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include National Research Council Canada.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Scientific and technological research is conducted for Canada's benefit. | 1916 | nrc.canada.ca | Ottawa, Canada |
Investor details for BioGene
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of BioGene
3 dated milestones of BioGene across 16 years, from founding to its latest funding, stage changes and deals.
- Founded BioGene is founded.
- Funding First funding round of $307K.
- Funding Latest funding round, Post-IPO, of $700K.
Web traffic of BioGene
The website of BioGene (biogene.com) receives about 2.8K visits a month.
- Monthly visits2.8K
▲ 1.7% vs previous month
Websites whose visitors overlap most with BioGene. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
taq-dna-polymerase.net | taq-dna-polymerase.net | 100% | – | ||
microbes.tistory.com | microbes.tistory.com | 100% | – | ||
syngendna.com | syngendna.com | 99% | – | ||
| bioxbio.com | 99% | #206,139 | View details | ||
pssbio.com | pssbio.com | 99% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for BioGene
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
2 companies that operate in the same segment as BioGene (Genomics & Gene Therapy Platforms) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biogene
Complete news archive for BioGene
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioGene
BioGene was founded in 1993 and raised its 1st funding round 14 years after it was founded.
BioGene is headquartered in Peterborough, United Kingdom.
BioGene is a molecular biology company based in Cambridge UK that manufactures reagents and instruments for assay design and development, DNARNA purification, amplification and analysis. As of September 2016, the company is also in the process of developing specialized instruments for direct PCR amplification from crude samples, and for POC detection of sepsis called QuRapID and QuType, respectively. Both the instruments are based on the companys proprietary UltraRapid PCR system that consists of a single tube DNA extraction and PCR process and associated reagents and instrumentation. QuRapID is designed for rapid identification of bacteria directly from primary samples using a multiplexed RT-PCR approach. QuType is in development as a POC device for simple and rapid diagnosis of sepsis in patients using the UltraRapid PCR platform.
BioGene offers CENOS and SoftGenetics Solutions.
BioGene has 1 investor. Key investors include National Research Council Canada.
BioGene operates through Biogene Limited.